Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Launched by NEW YORK MEDICAL COLLEGE · Feb 22, 2022

Keywords

ClinConnect Summary

The clinical trial titled "Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma" is studying a new approach to treating certain types of lymphoma, specifically non-Hodgkin lymphoma and Hodgkin lymphoma, in children, adolescents, and young adults. The goal is to see if adding a targeted immunotherapy (a type of treatment that helps the immune system fight cancer) to the standard treatment can safely reduce the amount of anthracycline (a chemotherapy drug) needed while still effectively controlling the disease.

To participate, patients must be newly diagnosed with specific types of lymphoma, such as Burkitt lymphoma or classical Hodgkin lymphoma, and meet certain health criteria. The trial is currently recruiting participants aged between 1 and 25 years, and it’s open to all genders. Those who join the study can expect to receive the new treatment alongside standard care, with close monitoring to ensure their safety and health. This trial offers a hopeful option for young patients facing these challenging cancers.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• * Newly diagnosed patients with histologically or cytologically proven newly diagnosed MB-NHL or cHL according to WHO Classification who meet the following criteria are eligible:
• COHORT I:
• • Burkitt lymphoma (ICD-O 9687/3) Burkitt-like lymphoma with 11q aberration (ICD-O 9687/3) Diffuse large B-cell lymphoma, NOS (ICD-O 9680/3) High grade B-cell lymphoma (ICD-O 9680/3)
• • COHORT Ia: stage III with LDH ≥ 2 ULN OR stage IV (5-24% bone marrow lymphoma infiltration) (GROUP B)61
• • COHORT Ib: any CNS involvement and/or BM involvement (≥ 25% lymphoma cells) (GROUP C)61 OR patients with less than 20% tumor size reduction post chemotherapy with cyclophosphamide, dexamethasone, vincristine (DOC Reduction for Cohort Ia).
• • COHORT II Classical Hodgkin lymphoma (ICD-O 9650/3, 9663/3, 9651/3, 9652/3, 9653/3)
• • COHORT IIa: stage I-IIA with bulky ± E, I-IIB no bulky ± E, IIIA ± E (INTERMEDIATE RISK)
• • COHORT IIb: stage IIB with bulky ± E, IIIA with bulky ± E, IIIB, IV (HIGH RISK)
• • Adequate organ function
• Exclusion Criteria:
• • Primary mediastinal B-cell lymphoma (PMBL)
• • T-cell/histiocyte-rich large B-cell lymphoma
• • Gray zone lymphoma
• • Follicular lymphoma
• • Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL)
• • Posttransplant lymphoproliferative lymphoma (PTLD)